Inhibition of cfu-gm growth by idarubicinol containing plasma samples obtained from poor prognosis lymphoma patients treated with 3-days infusion idarubicin

C. Corsini, P. Mancuso, M. Ghielmini, M. Zucchetti, F. Tealdo, E. Cocorocchio, P. F. Ferrucci, F. Peccatori, M. D'Lncalci, G. Martinelli

Research output: Contribution to journalArticle

Abstract

We have treated 14 patients with poor prognosis HD or NHL in a phase l-ll trial of high dose idarubicin and melphalan, with idarubicin dose-escalation. In order to verify the optimal timing of hematopoietic progenitors (HP) transplant, we studied the hematotoxic potential of idarubicinol (IDOL). We first performed cytotoxicity tests on clonogeneic cells derived from human umbilical cord blood. We then evaluated the myelotoxic effect of plasma samples drawn from patients on the day of transplant and on the subsequent two days. IDOL concentrations were measured in plasma by HPLC The median ID70 for CFU-GM was 130 ng/ml (range 80-170) after 1h and 12 ng/ml (range 7-17) after 24 h exposure to IDOL. CFU-GM performed after exposure to plasma samples showed a median growth inhibition of only 20% (range 0-43) on the day of transplantation when the median IDOL level was 11.15 ng/ml (range 3.3-17.4). On day +2 there was a marked reduction of plasma samples cytotoxicity with a median colony inhibition of 11% (range 0-32) and a median IDOL level of 6.9 ng/ml (range 3.2-114). The reduced in vitro toxicity of plasma samples compared to what expected from the dose-response curves, was not related to a protective effect of albumin on HP: the pattern of IDOL myelotoxicity was similar incubating HP in presence or in absence of human serum albumin. All patients achieved a rapid and sustained hematopoietic recovery with a median time to 1x10 WBC/I and 10x109 PLT/I of 13 days (range 10-17) and 13.5 days (range 11-19) respectively. These data suggest a discrepancy between in vitro and in vivo chemosensitivity of HP possibly explainable by the presence of circulating growth factors or HP interaction with the stromal environment in the in vivo condition.

Original languageEnglish
Pages (from-to)785
Number of pages1
JournalExperimental Hematology
Volume26
Issue number8
Publication statusPublished - 1998

Fingerprint

Idarubicin
Lymphoma
Growth
Granulocyte-Macrophage Progenitor Cells
Transplants
Melphalan
Fetal Blood
Serum Albumin
idarubicinol
Albumins
Intercellular Signaling Peptides and Proteins
Transplantation
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

@article{1860395e90da42e5b3e9e6814b6468a5,
title = "Inhibition of cfu-gm growth by idarubicinol containing plasma samples obtained from poor prognosis lymphoma patients treated with 3-days infusion idarubicin",
abstract = "We have treated 14 patients with poor prognosis HD or NHL in a phase l-ll trial of high dose idarubicin and melphalan, with idarubicin dose-escalation. In order to verify the optimal timing of hematopoietic progenitors (HP) transplant, we studied the hematotoxic potential of idarubicinol (IDOL). We first performed cytotoxicity tests on clonogeneic cells derived from human umbilical cord blood. We then evaluated the myelotoxic effect of plasma samples drawn from patients on the day of transplant and on the subsequent two days. IDOL concentrations were measured in plasma by HPLC The median ID70 for CFU-GM was 130 ng/ml (range 80-170) after 1h and 12 ng/ml (range 7-17) after 24 h exposure to IDOL. CFU-GM performed after exposure to plasma samples showed a median growth inhibition of only 20{\%} (range 0-43) on the day of transplantation when the median IDOL level was 11.15 ng/ml (range 3.3-17.4). On day +2 there was a marked reduction of plasma samples cytotoxicity with a median colony inhibition of 11{\%} (range 0-32) and a median IDOL level of 6.9 ng/ml (range 3.2-114). The reduced in vitro toxicity of plasma samples compared to what expected from the dose-response curves, was not related to a protective effect of albumin on HP: the pattern of IDOL myelotoxicity was similar incubating HP in presence or in absence of human serum albumin. All patients achieved a rapid and sustained hematopoietic recovery with a median time to 1x10 WBC/I and 10x109 PLT/I of 13 days (range 10-17) and 13.5 days (range 11-19) respectively. These data suggest a discrepancy between in vitro and in vivo chemosensitivity of HP possibly explainable by the presence of circulating growth factors or HP interaction with the stromal environment in the in vivo condition.",
author = "C. Corsini and P. Mancuso and M. Ghielmini and M. Zucchetti and F. Tealdo and E. Cocorocchio and Ferrucci, {P. F.} and F. Peccatori and M. D'Lncalci and G. Martinelli",
year = "1998",
language = "English",
volume = "26",
pages = "785",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of cfu-gm growth by idarubicinol containing plasma samples obtained from poor prognosis lymphoma patients treated with 3-days infusion idarubicin

AU - Corsini, C.

AU - Mancuso, P.

AU - Ghielmini, M.

AU - Zucchetti, M.

AU - Tealdo, F.

AU - Cocorocchio, E.

AU - Ferrucci, P. F.

AU - Peccatori, F.

AU - D'Lncalci, M.

AU - Martinelli, G.

PY - 1998

Y1 - 1998

N2 - We have treated 14 patients with poor prognosis HD or NHL in a phase l-ll trial of high dose idarubicin and melphalan, with idarubicin dose-escalation. In order to verify the optimal timing of hematopoietic progenitors (HP) transplant, we studied the hematotoxic potential of idarubicinol (IDOL). We first performed cytotoxicity tests on clonogeneic cells derived from human umbilical cord blood. We then evaluated the myelotoxic effect of plasma samples drawn from patients on the day of transplant and on the subsequent two days. IDOL concentrations were measured in plasma by HPLC The median ID70 for CFU-GM was 130 ng/ml (range 80-170) after 1h and 12 ng/ml (range 7-17) after 24 h exposure to IDOL. CFU-GM performed after exposure to plasma samples showed a median growth inhibition of only 20% (range 0-43) on the day of transplantation when the median IDOL level was 11.15 ng/ml (range 3.3-17.4). On day +2 there was a marked reduction of plasma samples cytotoxicity with a median colony inhibition of 11% (range 0-32) and a median IDOL level of 6.9 ng/ml (range 3.2-114). The reduced in vitro toxicity of plasma samples compared to what expected from the dose-response curves, was not related to a protective effect of albumin on HP: the pattern of IDOL myelotoxicity was similar incubating HP in presence or in absence of human serum albumin. All patients achieved a rapid and sustained hematopoietic recovery with a median time to 1x10 WBC/I and 10x109 PLT/I of 13 days (range 10-17) and 13.5 days (range 11-19) respectively. These data suggest a discrepancy between in vitro and in vivo chemosensitivity of HP possibly explainable by the presence of circulating growth factors or HP interaction with the stromal environment in the in vivo condition.

AB - We have treated 14 patients with poor prognosis HD or NHL in a phase l-ll trial of high dose idarubicin and melphalan, with idarubicin dose-escalation. In order to verify the optimal timing of hematopoietic progenitors (HP) transplant, we studied the hematotoxic potential of idarubicinol (IDOL). We first performed cytotoxicity tests on clonogeneic cells derived from human umbilical cord blood. We then evaluated the myelotoxic effect of plasma samples drawn from patients on the day of transplant and on the subsequent two days. IDOL concentrations were measured in plasma by HPLC The median ID70 for CFU-GM was 130 ng/ml (range 80-170) after 1h and 12 ng/ml (range 7-17) after 24 h exposure to IDOL. CFU-GM performed after exposure to plasma samples showed a median growth inhibition of only 20% (range 0-43) on the day of transplantation when the median IDOL level was 11.15 ng/ml (range 3.3-17.4). On day +2 there was a marked reduction of plasma samples cytotoxicity with a median colony inhibition of 11% (range 0-32) and a median IDOL level of 6.9 ng/ml (range 3.2-114). The reduced in vitro toxicity of plasma samples compared to what expected from the dose-response curves, was not related to a protective effect of albumin on HP: the pattern of IDOL myelotoxicity was similar incubating HP in presence or in absence of human serum albumin. All patients achieved a rapid and sustained hematopoietic recovery with a median time to 1x10 WBC/I and 10x109 PLT/I of 13 days (range 10-17) and 13.5 days (range 11-19) respectively. These data suggest a discrepancy between in vitro and in vivo chemosensitivity of HP possibly explainable by the presence of circulating growth factors or HP interaction with the stromal environment in the in vivo condition.

UR - http://www.scopus.com/inward/record.url?scp=33748610540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748610540&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 785

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 8

ER -